ES2484720T3 - Marcadores moleculares para infecciones de las vías urinarias - Google Patents
Marcadores moleculares para infecciones de las vías urinarias Download PDFInfo
- Publication number
- ES2484720T3 ES2484720T3 ES11713086.4T ES11713086T ES2484720T3 ES 2484720 T3 ES2484720 T3 ES 2484720T3 ES 11713086 T ES11713086 T ES 11713086T ES 2484720 T3 ES2484720 T3 ES 2484720T3
- Authority
- ES
- Spain
- Prior art keywords
- procalcitonin
- concentration
- urinary tract
- urine
- urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019206 urinary tract infection Diseases 0.000 title claims abstract description 57
- 108010048233 Procalcitonin Proteins 0.000 claims abstract description 105
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims abstract description 105
- 210000002700 urine Anatomy 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000003745 diagnosis Methods 0.000 claims abstract description 18
- 238000012544 monitoring process Methods 0.000 claims abstract description 12
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 230000002485 urinary effect Effects 0.000 claims description 32
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 12
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 claims description 12
- 229910052693 Europium Inorganic materials 0.000 claims description 8
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052772 Samarium Inorganic materials 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 6
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 101100311210 Mus musculus Stard10 gene Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000003126 Anuria Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000037194 Fever of Unknown Origin Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012273 nephrostomy Methods 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/348—Urinary tract infections
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000121A ITRM20100121A1 (it) | 2010-03-18 | 2010-03-18 | Marcatori molecolari per infezioni delle vie urinarie. |
| ITRM20100121 | 2010-03-18 | ||
| PCT/IB2011/051073 WO2011114287A2 (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2484720T3 true ES2484720T3 (es) | 2014-08-12 |
Family
ID=42630320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11713086.4T Active ES2484720T3 (es) | 2010-03-18 | 2011-03-15 | Marcadores moleculares para infecciones de las vías urinarias |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8748195B2 (https=) |
| EP (1) | EP2548031B1 (https=) |
| JP (1) | JP5681219B2 (https=) |
| CN (1) | CN102939542B (https=) |
| BR (1) | BR112012023485B1 (https=) |
| ES (1) | ES2484720T3 (https=) |
| IT (1) | ITRM20100121A1 (https=) |
| RU (1) | RU2611371C2 (https=) |
| WO (1) | WO2011114287A2 (https=) |
| ZA (1) | ZA201206633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2592228C2 (ru) * | 2014-04-10 | 2016-07-20 | Владимир Игоревич Павлов | Способ (варианты) и набор для диагностики инфекции мочевыводящих путей, способ лечения и определения предрасположенности к инфекции мочевыводящих путей |
| RU2679629C1 (ru) * | 2018-07-05 | 2019-02-12 | Антонина Ни | Способ диагностики воспалительного процесса органов мочевыделительной системы у детей раннего возраста |
| RU2724186C1 (ru) * | 2020-01-23 | 2020-06-22 | Наталья Борисовна Гусева | Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы |
| RU2766811C1 (ru) * | 2021-06-22 | 2022-03-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ применения маркеров бактериального воспаления для диагностики инфекции мочевыводящих путей у детей первых трех лет жизни |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| CA2623523C (en) * | 2005-09-28 | 2019-02-12 | Becton, Dickinson And Company | Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition |
| DE102007009751A1 (de) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
| US8383332B2 (en) * | 2009-10-13 | 2013-02-26 | B.R.A.H.M.S. Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack |
| EP2545379B1 (en) * | 2010-03-08 | 2015-09-30 | B.R.A.H.M.S GmbH | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
| CN103096816B (zh) * | 2010-05-04 | 2016-10-12 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
-
2010
- 2010-03-18 IT IT000121A patent/ITRM20100121A1/it unknown
-
2011
- 2011-03-15 US US13/635,521 patent/US8748195B2/en active Active
- 2011-03-15 CN CN201180014501.XA patent/CN102939542B/zh active Active
- 2011-03-15 JP JP2012557648A patent/JP5681219B2/ja active Active
- 2011-03-15 RU RU2012144233A patent/RU2611371C2/ru active
- 2011-03-15 EP EP11713086.4A patent/EP2548031B1/en active Active
- 2011-03-15 BR BR112012023485-4A patent/BR112012023485B1/pt active IP Right Grant
- 2011-03-15 ES ES11713086.4T patent/ES2484720T3/es active Active
- 2011-03-15 WO PCT/IB2011/051073 patent/WO2011114287A2/en not_active Ceased
-
2012
- 2012-09-04 ZA ZA2012/06633A patent/ZA201206633B/en unknown
-
2014
- 2014-05-01 US US14/267,366 patent/US20140242725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8748195B2 (en) | 2014-06-10 |
| CN102939542A (zh) | 2013-02-20 |
| HK1180392A1 (en) | 2013-10-18 |
| JP2013522618A (ja) | 2013-06-13 |
| ZA201206633B (en) | 2015-04-29 |
| WO2011114287A3 (en) | 2011-12-15 |
| RU2012144233A (ru) | 2014-04-27 |
| US20140242725A1 (en) | 2014-08-28 |
| ITRM20100121A1 (it) | 2011-09-19 |
| BR112012023485A2 (pt) | 2016-05-24 |
| BR112012023485B1 (pt) | 2020-03-17 |
| WO2011114287A2 (en) | 2011-09-22 |
| RU2611371C2 (ru) | 2017-02-21 |
| CN102939542B (zh) | 2015-07-08 |
| US20130084650A1 (en) | 2013-04-04 |
| EP2548031A2 (en) | 2013-01-23 |
| EP2548031B1 (en) | 2014-05-21 |
| JP5681219B2 (ja) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jekarl et al. | Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis | |
| ES2976232T3 (es) | Métodos y dispositivos mejorados para un diagnóstico exacto de infecciones | |
| Shehabi et al. | Pro/Con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? | |
| Chan et al. | Procalcitonin as a marker of bacterial infection in the emergency department: an observational study | |
| ES2386966T3 (es) | Método para diagnosticar enfermedades infecciosas midiendo el nivel de TREM-1 soluble en una muestra | |
| ES2293444T3 (es) | Sistema de test diagnostico para la deteccion de anticuerpos contra infecciones respiratorias agudas y neumonias atipicas. | |
| Nakamura et al. | Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury | |
| ES2944613T3 (es) | proADM y/o histonas como marcadores indicadores de un acontecimiento adverso | |
| US20130288276A1 (en) | Method for prediction of prognosis of sepsis | |
| ES2484720T3 (es) | Marcadores moleculares para infecciones de las vías urinarias | |
| US20140120174A1 (en) | Methods of prognosis and diagnosis of sepsis | |
| US20130149725A1 (en) | Methods and compositions for diagnosis of urosepsis and urinary tract infection | |
| ES2764080T3 (es) | Deshidrogenasa y toxina de Clostridium difficile como un biomarcador | |
| Chivate et al. | Procalcitonin as a marker for the diagnosis of sepsis | |
| Matha et al. | The utility of procalcitonin in the prediction of serious bacterial infection in a tertiary paediatric intensive care unit | |
| Elsayed et al. | Heparin binding protein as a predictive marker for sepsis and septic shock in critically ill patients: a cross sectional study | |
| Hausfater et al. | Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays | |
| JP2024020276A (ja) | 歯肉炎の診断方法、使用、キット | |
| HK1180392B (en) | Molecular markers for urinary tract infections | |
| CN109696551B (zh) | 用于脑中风诊断或预后评价的体外检测设备 | |
| Salleeh et al. | Duration of fever affects the likelihood of a positive bag urinalysis or catheter culture in young children | |
| CN112114138A (zh) | 一种儿童肺炎支原体抗原的检测试剂盒及检测方法 | |
| Vincent et al. | Sepsis biomarkers | |
| Prokop et al. | The usefulness of fast point-of-care tests detecting calprotectin in synovial fluid for diagnosing periprosthetic joint infections | |
| Venge | Human Neutrophil Lipocalin (HNL) in the Distinction between Bacterial and Viral Infections |